FDA Approves Deciphera’s Qinlock for Gastrointestinal Stromal Tumor

May 19, 2020

The FDA approved Decipharma Pharmaceuticals’ Qinlock (ripretinib) as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST).

The approval was based on the results of a study of 129 patients with advanced GIST who received prior treatment with imatinib, sunitinib, and regorafenib.

Progression-free survival in participants taking Qinlock was 6.3 months, compared to one month for those taking placebo.

Qinlock was granted priority review, fast track, and breakthrough therapy designations.

View today's stories